| Code | CSB-RA004929MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to lumrotatug, targeting CD38, a type II transmembrane glycoprotein expressed on various immune cells and hematological malignancies. CD38 functions as both an ectoenzyme involved in NAD+ metabolism and calcium signaling, and as a receptor mediating cell adhesion and signal transduction. This multifunctional protein plays critical roles in immune regulation, cell proliferation, and survival. CD38 is highly expressed in multiple myeloma, chronic lymphocytic leukemia, and other B-cell malignancies, making it a valuable therapeutic target and biomarker in hematological research.
Lumrotatug represents a therapeutic antibody designed to bind CD38 with high specificity, demonstrating potential mechanisms including antibody-dependent cellular cytotoxicity and direct apoptosis induction in target cells. This biosimilar provides researchers with a reliable tool for investigating CD38-mediated pathways, exploring immune cell function, studying hematological malignancies, and evaluating antibody-based therapeutic strategies. The antibody supports diverse research applications in oncology, immunology, and cell biology studies focused on understanding CD38's role in disease pathogenesis and treatment responses.
There are currently no reviews for this product.